Collegium to Present Phase 4 AZSTARYS Studies in Children With ADHD

PUBT · 1d ago
Collegium to Present Phase 4 AZSTARYS Studies in Children With ADHD
  • Collegium Pharmaceutical will present seven ADHD research abstracts at AACAP’s October 26-31, 2026, annual meeting and NEI’s November 5-8 congress.
  • Pediatric Phase 4 studies examine Azstarys’ safety, tolerability and efficacy, including in children aged 4-5.
  • Real-world research examines adult Jornay PM treatment persistence, morning functioning and caregiver strain; investigators characterize the observational findings as hypothesis-generating.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210800PRIMZONEFULLFEED9849822) on October 21, 2026, and is solely responsible for the information contained therein.